Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Published 2015 View Full Article

Authors

Keywords

AMG 386, trebananib, bevacizumab, paclitaxel, HER2-negative

Journal

BREAST

Volume 24, Issue 3, Pages 182-190

Publisher

Elsevier BV

Online

2015-03-05

DOI

10.1016/j.breast.2014.11.003

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now